Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: Experience with tigecycline

Journal of Chemotherapy

Volumn 21, Issue 1, 2009, Pages 58-62

  Curcio, Daniel ^a,e   Fernandez, F ^a   Vergara, J ^b   Vazquez, W ^c   Luna, C M ^d  

^a Sanatorio San Jose   (Argentina)

^b HOSPITAL RAMOS MEJÍA   (Argentina)

^c HOSPITAL ESPAÑOL DE MENDOZA   (Argentina)

^d HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^e NONE   (Argentina)

Author keywords

Acinetobacter spp.; Tigecycline; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; IMIPENEM; MEROPENEM; MINOCYCLINE; TIGECYCLINE;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; INTENSIVE CARE; INTERMETHOD COMPARISON; LOADING DRUG DOSE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 63049101658     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.1.58     Document Type: Article

References (14)

1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. As nosocomial pathogens: microbiological, clinical and epidemiological features. Clin Microbiol Rev 1996;344:1329-32.
2. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589-601.
3. Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470-80.
4. Curcio D, Fernández F, Duret F. Initial use of tigecycline in Argentina. Rev Chilena Infectol. 2007;24(6):497-9.
5. Clinical and Laboratory Standards Institute. 2007. M100-S17: performance standards for antimicrobial susceptibility testing, 17th informational supplement. CLSI, Wayne, PA.
6. Lemeshow S, Teres D, Klar J, et al. Mortality probability models (MPM II) based on an international cohort of intensive care patients. JAMA 1993;270:2478-86.
7. Bantar C, Famiglietti A, Goldberg M. Three-year surveillance study of nosocomial bacterial resistance in Argentina. The Antimicrobial Committee; and the National Surveillance Program (SIR) Participants Group. Int J Infect Dis. 2000;4(2):85-90.
8. Pasterán F, Rapoport M, Petroni A et al. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother 2006;50: 3222-4.
9. Song JY, Kee SY, Hwang IS, et al. In vitro activities of carbapenem/ sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;60(2):317-22.
10. Ratnam I, Franklin C, Spelman DW. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit. Pathology 2007; 39: 586-8.
11. Conte JE, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25(6):523-9.
12. Schafer JJ, Goff DA, Stevenson KB, et al. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy. 2007;27(7):980-7.
13. Rué M, Artigas A, Alvarez M, et al. Performance of the Mortality Probability Models in assesing severity of iones during the first week in the intensive care unit. Crit Care Med 2000;28(8):2819-24.
14. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C.. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1249-56.